Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wyeth lives and learns in trial development

Executive Summary

Wyeth is reaping the benefits of its "learn and confirm" approach to clinical development, U.S. President Geno Germano tells analysts during a June 12 presentation at the Goldman Sachs Global Healthcare Conference. The firm announced last year it was replacing its three-phase development process with "learn and confirm" to better understand the medical value of a molecule up-front (1"The Pink Sheet" July 3, 2006, p. 19). Wyeth and other pharma companies have touted adaptive trial designs as a way to streamline the clinical development process and decrease the time and length of trials. That approach may eliminate agents that could fail on a larger scale later in development, Germano points out. For instance, "in one of our programs where we initiated an adaptive trial design, we were able to explore multiple dose ranges for a given product and determined that frankly it didn't have the activity that we thought it would have," he noted. "And while that's unfortunate, the good news is it's unfortunate at several million dollars less cost than it would be if we were to find out using a traditional approach to dose ranges and dose-finding studies"...

You may also be interested in...

Wyeth Replacing Three-Phase Development With “Learn And Confirm” Model

Wyeth is moving to a "learn and confirm" paradigm for clinical development that will focus on better understanding the medical value of a molecule up-front

Largest PBMs Eliminate Consumers’ Cost Sharing For Opill On Most Commercial Plans

Decisions by “big three” PBMs suggest they’re taking proactive steps to comply with potential HRSA rulemaking to require most health plans, under Affordable Care Act regulations, to cover Opill and other types of OTC birth control without cost sharing.

First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations

With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts